TaiGen Biotechnology and HEC Pharmaceutical execute equity purchase agreement for HCV-focused JV

Taipei, Taiwan-headquartered TaiGen Biotechnology Co., Ltd. announced today that its wholly owned Chinese subsidiary, TaiGen Biopharmaceuticals Co. (Beijing), Ltd. has executed an equity purchase agreement to sell its 9% equity stake in Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd., a joint venture company between TGBJ and HEC, to Chinese pharma company YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

Read more